Moreover, in the context of hepatic insulin resistance, bardoxolone-methyl (CDDO-Me), a derivative of the natural oleanolic acid, showed to be promising in clinical trials with patients suffering from diabetic chronic kidney disease through Nrf2 activation [158]. Here, NFE2L2 is linked to Insulin resistance.